2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. Calcium Channel
  5. T-type calcium channel Isoform

T-type calcium channel

 

T-type calcium channel Related Products (29):

Cat. No. Product Name Effect Purity
  • HY-B0166
    L-Ascorbic acid
    		Inhibitor 99.97%
    L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
  • HY-B0166A
    L-Ascorbic acid sodium salt
    		Inhibitor 99.97%
    L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor.
  • HY-15553A
    Mibefradil dihydrochloride
    		Inhibitor ≥98.0%
    Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels (IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively).
  • HY-50722
    NNC 55-0396
    		Inhibitor ≥99.0%
    NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research.
  • HY-B0358A
    Flunarizine dihydrochloride
    		Inhibitor 99.87%
    Flunarizine dihydrochloride is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
  • HY-126401
    Elgodipine
    		Inhibitor
    Elgodipine (IQB-875 free base) is an orally active dihydropyridine calcium antagonist and an antianginal compound. Elgodipine inhibits both T- and L-type calcium channels (IC50: 32 and 2.3 nM). Elgodipine lowers systemic vascular resistance and improves systolic cardiac function.
  • HY-17403
    Manidipine dihydrochloride
    		Inhibitor 99.91%
    Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC50 = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection.
  • HY-B1378
    Ethosuximide
    		Inhibitor 99.26%
    Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
  • HY-120546
    Ulixacaltamide
    		Antagonist 98.73%
    Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief.
  • HY-103309
    ML218
    		Inhibitor 99.49%
    ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier.
  • HY-12502A
    Efonidipine hydrochloride monoethanolate
    		Inhibitor 99.83%
    Efonidipine hydrochloride monoethanolate (NZ-105 hydrochloride monoethanolate) is a dual T-type and L-type calcium channel blocker (CCB).
  • HY-B0768A
    Lomerizine dihydrochloride
    		Antagonist 99.84%
    Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
  • HY-101096
    Suvecaltamide
    		Inhibitor 99.96%
    Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth.
  • HY-A0092
    Trimethadione
    		Inhibitor ≥98.0%
    Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects.
  • HY-W011235
    Norfluoxetine hydrochloride
    		Inhibitor 99.58%
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity.
  • HY-112723
    Apinocaltamide
    		Antagonist 99.83%
    Apinocaltamide (ACT-709478) is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker. ACT-709478 is used in the research of generalized epilepsies.
  • HY-19721
    ABT-639
    		Inhibitor 99.32%
    ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker.
  • HY-W032013
    1-Octanol
    		Inhibitor 99.63%
    1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents. 1-Octanol is a highly attractive biofuel with diesel-like properties.
  • HY-115681
    (2R/S)-6-PNG
    		Inhibitor 99.88%
    (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice.
  • HY-120597
    SAK3
    		Activator ≥99.0%
    SAK3 is a potent T-type voltage-gated Ca2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice. SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity.